•
Sisram Medical Ltd (HKG: 1696), an Israel-based subsidiary of the Fosun Pharmaceutical Group, has released its unaudited interim financial report for 2024, showing revenues of USD 168.7 million, a slight decrease of 1.7% year-on-year (YOY). The company’s regional revenue breakdown indicates growth in the Asia Pacific, Europe, Middle East, and…